Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nascent Biotech Inc (OP: NBIO )

0.0681 -0.0119 (-14.88%)
Streaming Delayed Price Updated: 10:04 AM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nascent Biotech Inc

< Previous 1 2 Next >
Nascent Biotech Presents at the July Emerging Growth Conference
Via ACCESSWIRE
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
Via ACCESSWIRE
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
Via ACCESSWIRE
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
Via ACCESSWIRE
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Via ACCESSWIRE
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
Via ACCESSWIRE
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
Via ACCESSWIRE
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
Via ACCESSWIRE
Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
Via ACCESSWIRE
Nascent Biotech Regains Worldwide Rights for Pritumumab
Via ACCESSWIRE
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
Via ACCESSWIRE
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
Via ACCESSWIRE
Nascent Announces the Completion of Its Phase1 Clinical Trials
Via ACCESSWIRE
Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
Via ACCESSWIRE
Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
Via ACCESSWIRE
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
Via ACCESSWIRE
Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
Via ACCESSWIRE
Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
Via ACCESSWIRE
Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
Via ACCESSWIRE
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
Via ACCESSWIRE
Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
VERO BEACH, FL / ACCESSWIRE / July 19, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of... 
From Nascent Biotech Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of... 
From Nascent Biotech Inc.
Via AccessWire
Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Nascent Biotech Inc.
Via AccessWire
Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
VERO BEACH, FL / ACCESSWIRE / April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc... 
From Nascent Biotech Inc.
Via AccessWire
The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial
SAN DIEGO, CA / ACCESSWIRE / March 8, 2022 / Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational... 
From Nascent Biotech Inc.
Via AccessWire
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
Milestone Payment is the Second of Four in $5M Pritumumab Licensing Deal VERO BEACH, FL / ACCESSWIRE / February 23, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the... 
From Nascent Biotech Inc.
Via AccessWire
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development... 
From Nascent Biotech Inc.
Via AccessWire
Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration
SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome... 
From Nascent Biotech Inc.
Via AccessWire
Exposures COVID-19
Marble Arch Research Publishes Analyst Research Report on Nascent Biotech
VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of... 
From Nascent Biotech Inc.
Via AccessWire
Exposures COVID-19
Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of... 
From Nascent Biotech Inc.
Via AccessWire
Exposures COVID-19
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.